⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SLXN News
Silexion Therapeutics Corp Ordinary Shares
Form 8-K
sec.gov
SLXNW
SLXN
Form 8-K
sec.gov
SLXNW
SLXN
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
SLXN
Form 8-K
sec.gov
SLXN
SLXNW
Form 8-K
sec.gov
SLXN
SLXNW
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
globenewswire.com
SLXN
Form 8-K
sec.gov
SLXN
SLXNW
Form 8-K
sec.gov
SLXN
SLXNW
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers
globenewswire.com
SLXN
Form 8-K
sec.gov
SLXNW
SLXN